{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:33:32Z","timestamp":1761129212774,"version":"3.40.5"},"reference-count":57,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            We investigated the efficacy of posaconazole prophylaxis in preventing invasive aspergillosis due to azole-resistant\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Aspergillus fumigatus<\/jats:named-content>\n            isolates. Using a neutropenic murine model of pulmonary infection, posaconazole prophylaxis was evaluated using three isogenic clinical isolates, with posaconazole MICs of 0.063 mg\/liter (wild type), 0.5 mg\/liter (F219I mutation), and 16 mg\/liter. A fourth isolate harboring TR\n            <jats:sub>34<\/jats:sub>\n            \/L98H (MIC of 0.5 mg\/liter) was also tested. Posaconazole prophylaxis was effective in\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">A. fumigatus<\/jats:named-content>\n            with posaconazole MICs of \u22640.5 mg\/liter, where 100% survival was reached. However, breakthrough infection was observed in mice infected with the isolate for which the posaconazole MIC was &gt;16 mg\/liter.\n          <\/jats:p>","DOI":"10.1128\/aac.03850-14","type":"journal-article","created":{"date-parts":[[2014,12,23]],"date-time":"2014-12-23T03:11:33Z","timestamp":1419304293000},"page":"1487-1494","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":21,"title":["Posaconazole Prophylaxis in Experimental Azole-Resistant Invasive Pulmonary Aspergillosis"],"prefix":"10.1128","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6194-7447","authenticated-orcid":false,"given":"Seyedmojtaba","family":"Seyedmousavi","sequence":"first","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands"},{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6736-4149","authenticated-orcid":false,"given":"Johan W.","family":"Mouton","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands"},{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem J. G.","family":"Melchers","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E.","family":"Verweij","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200401-093OC"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.3.608"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(02)00035-1"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1710.110226"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2014.06.001"},{"key":"e_1_3_2_7_2","volume-title":"European public assessment report (EPAR) for Noxafil, 06\/09\/2012","author":"European Medicines Agency","year":"2012","unstructured":"European Medicines Agency. 2012. European public assessment report (EPAR) for Noxafil, 06\/09\/2012. European Medicines Agency, London, United Kingdom."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/525258"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020191"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.11.118"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050219"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61055-1"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/597465"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01017-12"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1507.090043"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780802545600"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.17.36.20262-en"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc061720"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.17.48.20326-en"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit320"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01430-12"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00606-10"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00931-09"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir023"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.08.017"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200212263472618"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.00231-09"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70265-8"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.64"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.100263"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2013.826989"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05088-11"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02226-12"},{"key":"e_1_3_2_36_2","volume-title":"EUCAST definitive document E. Def 9.1: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds","author":"Rodriguez-Tudela JL","year":"2008","unstructured":"Rodriguez-Tudela JL, Arendrup MC, Arikan S, Barchiesi F, Bille J, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Denning DW, Donnelly JP, Fegeler W, Lass-Fl\u00f6rl C, Moore C, Richardson M, Gaustad P, Schmalreck A, Velegraki A, Verweij P. 2008. EUCAST definitive document E. Def 9.1: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. European Committee for Antimicrobial Susceptibility Testing (EUCAST), Vaxjo, Sweden. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/4ESCMID_Library\/3Publications\/EUCAST_Documents\/Other_Documents\/EUCAST_moulds_DEFINITIVE_document_V_ISO_April_08%20final.pdf."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.2.478-484.2001"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.2788-2795.2003"},{"key":"e_1_3_2_39_2","first-page":"151","article-title":"Higher than predicted posaconazole penetration at the infection site in a murine model of invasive pulmonary aspergillosis","volume":"56","author":"Seyedmousavi S","year":"2013","unstructured":"Seyedmousavi S, Bruggemann RJM, Melchers WJG, Verweij PE, Mouton JW. 2013. Higher than predicted posaconazole penetration at the infection site in a murine model of invasive pulmonary aspergillosis. Mycoses 56:151.","journal-title":"Mycoses"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00053-14"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2011.08.001"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2012.01.015"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00133-06"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.2165\/11594090-000000000-00000"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00009.2003"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1986.60.2.532"},{"key":"e_1_3_2_47_2","first-page":"L617","article-title":"Quantitative assessment of epithelial lining fluid in the lung","volume":"263","author":"Chinard FP","year":"1992","unstructured":"Chinard FP. 1992. Quantitative assessment of epithelial lining fluid in the lung. Am J Physiol 263:L617\u2013L618.","journal-title":"Am J Physiol"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/147.1.148"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03752.x"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00663-08"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01396-09"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01407-09"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00637-11"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050034"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072280"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01279-12"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku364"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks402"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03850-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03850-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:50:35Z","timestamp":1645483835000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03850-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1128\/AAC.03850-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03850-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"2014-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-12-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-02-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}